You are here: Industry Insights > Market News > Chinese mainland reports 51 locally transmitted COVID-19 cases

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Chinese mainland reports 51 locally transmitted COVID-19 cases

NMPA/XinhuaDecember 15, 2021

Tag: Chinese , COVID-19 , imported cases

Favorites

The Chinese mainland on Monday reported 51 new locally transmitted COVID-19 cases, the National Health Commission said in its daily report on Dec 13.

Of the new local cases, 44 were reported in Zhejiang, five in Inner Mongolia, and one each in Heilongjiang and Shaanxi, the commission said.

Also reported were 25 new imported cases in eight provincial-level regions, according to the commission.

No new suspected cases or new deaths related to COVID-19 were reported on Monday, it added.

Previous:Pfizer Says Final Data Show COVID-19 Pill Stays Strong Against Severe Illness

Next:Packaging and Drug Delivery Trends - 5 key learning points for 2022

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Chinese mainland reports 51 locally transmitted COVID-19 cases | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

Top quality Chinese hawthorn fruit extract

Semen Cassiae Torae Anthraquinone Obtusifolia Powder Glauca Seeds Tora Chinese Cassia Seed Extract

Lobelia chinensis extract Chinese Lobelia Herb extract Lobelia extract Herba Lobeliae Chinensis extr

Chinese Traditional Natural Herb Huang Jing Siberian Solomonseal Rhizome Extract Powder

Cuscuta extract Semen Cuscutae extract dodder extract the seed of chinese dodder extract

Cordyceps Cordyceps sinensis Worm Grass Chinese Language Learning chinese caterpillar fungus extract

chinese popular famous chilli pepper factory supply dry cleaned dry red chili with different hot sco

Chinese Bilberry Extract

Chinese prickly ash extract

Chinese mainland reports 51 locally transmitted COVID-19 cases

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>